Medicenna Therapeutics Corp. (MDNAF) stock
Close on Oct 19, 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Mar 31, 2023
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Trading
- Previous close
- $0.30
- Open
- $0.33
- Day's range
- $0.27 – $0.33
- Volume
- 42,078
- Average volume (20 days)
- 67,985
Valuation needs the share price. It fills in once daily prices are connected and converted from CAD.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | MDNAF | S&P 500 | Difference | MDNAF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -8.5% | +0.6% | −9.1 pts | ||
| 3 months | +10.8% | +3.4% | +7.4 pts | ||
| Year to date | -58.7% | +13.3% | −72.0 pts | ||
| 1 year | -56.7% | +16.6% | −73.3 pts | ||
| 3 years | -8.5% | +86.4% | −94.9 pts | -2.9% | +23.1% |
| 5 years | -88.4% | +81.9% | −170.2 pts | -35.0% | +12.7% |
Five years at a glance
Fiscal years 2019 to 2023, CAD
EPS, diluted
Press releases
Releases Medicenna Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Medicenna Therapeutics
Pharmaceutical Preparations
Medicenna Therapeutics Corp. is a biotechnology company that develops engineered cytokine therapies for the treatment of cancer. The company focuses on designing selective interleukin-based molecules, including interleukin-2, interleukin-4, and interleukin-13 variants, either independently or combined with cell-killing proteins and antibodies. Its primary product candidates include MDNA11 for advanced solid tumors, bizaxofusp for recurrent glioblastoma, and bi-functional therapies termed BiSKITs. These investigational treatments are designed for cancer patients with advanced solid tumors and high-grade brain cancers.
Company profile, executives and historyMedicenna Therapeutics stock: common questions
What is Medicenna Therapeutics's stock price?
MDNAF closed at $0.28 on Oct 19, 2026, down 7.63% on the day.
Does Medicenna Therapeutics pay a dividend?
No. Medicenna Therapeutics has not paid a cash dividend over the last twelve months.
How has MDNAF stock performed over the past year?
Including dividends, MDNAF returned -56.7% over the past year, against +16.6% for the S&P 500.
Who are Medicenna Therapeutics's competitors?
Companies most similar to Medicenna Therapeutics by business, industry and size include BCTX, MBRX, KZIA, ERNA, LYEL.
See a number that looks wrong?